

CLAIMS

1. Use of a non-opioid analgesic for the manufacture of a medicament for the treatment of intermittent or episodic pain experienced by a patient undergoing chronic pain treatment with an opioid analgesic.
- 5 2. Use according to claim 1, wherein the pain is chronic benign pain.
3. Use according to claim 2, wherein the pain is related to a musculoskeletal, visceral or headache condition.
4. Use according to claim 3, wherein the condition is osteoarthritis, rheumatoid arthritis, chronic back pain, chronic pancreatitis or chronic migraine.
- 10 5. Use according to claim 1, wherein the pain is breakthrough pain in cancer.
6. Use according to claim 5, wherein the cancer breakthrough pain is primarily neuropathic.
7. Use according to any preceding claim, wherein the non-opioid analgesic is a potentiation of the opioid analgesic.
- 15 8. Use according to any preceding claim, wherein the non-opioid analgesic is selected from antagonists of NMDA, CCK, substance P or neurokinin, compounds that cause uptake blockade, agonists of alpha₂ or beta₂ adrenoceptors, and COX inhibitors.
9. Use according to any preceding claim, wherein the non-opioid analgesic
- 20 is selected from clenbuterol, proglumide, devazepide, ifenprodil, nefopam, tramadol, duloxetine and venlafaxine.
10. Use according to any preceding claim, wherein the medicament is for administration via a route that avoids first-pass metabolism.
11. Use according to claim 10, wherein the route is intranasal.
- 25 12. Use according to claim 10, wherein the route is sublingual.
13. Use according to claim 10, wherein the route is pulmonary.
14. A product comprising an opioid analgesic and a non-opioid analgesic, as a combined preparation for simultaneous, separate or sequential use in the treatment of chronic pain including intermittent or episodic pain.
- 30 15. A product according to claim 14, wherein the non-opioid analgesic is as defined in any of claims 7 to 9.